75 related articles for article (PubMed ID: 12211437)
1. Long-term predictions of the therapeutic equivalence of daily and less than daily alendronate dosing.
Hernandez CJ; Beaupré GS; Marcus R; Carter DR
J Bone Miner Res; 2002 Sep; 17(9):1662-6. PubMed ID: 12211437
[TBL] [Abstract][Full Text] [Related]
2. Therapeutic equivalence of alendronate 70 mg once-weekly and alendronate 10 mg daily in the treatment of osteoporosis. Alendronate Once-Weekly Study Group.
Schnitzer T; Bone HG; Crepaldi G; Adami S; McClung M; Kiel D; Felsenberg D; Recker RR; Tonino RP; Roux C; Pinchera A; Foldes AJ; Greenspan SL; Levine MA; Emkey R; Santora AC; Kaur A; Thompson DE; Yates J; Orloff JJ
Aging (Milano); 2000 Feb; 12(1):1-12. PubMed ID: 10746426
[TBL] [Abstract][Full Text] [Related]
3. Two-year results of once-weekly administration of alendronate 70 mg for the treatment of postmenopausal osteoporosis.
Rizzoli R; Greenspan SL; Bone G; Schnitzer TJ; Watts NB; Adami S; Foldes AJ; Roux C; Levine MA; Uebelhart B; Santora AC; Kaur A; Peverly CA; Orloff JJ;
J Bone Miner Res; 2002 Nov; 17(11):1988-96. PubMed ID: 12412806
[TBL] [Abstract][Full Text] [Related]
4. Patients with osteoporosis prefer once weekly to once daily dosing with alendronate.
Kendler D; Kung AW; Fuleihan Gel-H; González González JG; Gaines KA; Verbruggen N; Melton ME
Maturitas; 2004 Jul; 48(3):243-51. PubMed ID: 15207890
[TBL] [Abstract][Full Text] [Related]
5. Antiresorption therapy and reduction in fracture susceptibility in the osteoporotic elderly patient: open study.
Muscoso E; Puglisi N; Mamazza C; Lo Giudice F; Testai M; Abbate S; Santangelo A; Panebianco P; Maugeri D
Eur Rev Med Pharmacol Sci; 2004; 8(2):97-102. PubMed ID: 15267123
[TBL] [Abstract][Full Text] [Related]
6. Long-term skeletal effects of recombinant human growth hormone (rhGH) alone and rhGH combined with alendronate in GH-deficient adults: a seven-year follow-up study.
Biermasz NR; Hamdy NA; Pereira AM; Romijn JA; Roelfsema F
Clin Endocrinol (Oxf); 2004 May; 60(5):568-75. PubMed ID: 15104559
[TBL] [Abstract][Full Text] [Related]
7. Histomorphometric assessment of the long-term effects of alendronate on bone quality and remodeling in patients with osteoporosis.
Chavassieux PM; Arlot ME; Reda C; Wei L; Yates AJ; Meunier PJ
J Clin Invest; 1997 Sep; 100(6):1475-80. PubMed ID: 9294113
[TBL] [Abstract][Full Text] [Related]
8. Osteoporosis. Efficacy and safety of a bisphosphonate dosed once weekly.
Baran D
Geriatrics; 2001 Mar; 56(3):28-32. PubMed ID: 11252758
[TBL] [Abstract][Full Text] [Related]
9. [Simulation through the method of finite element of alendronate in a model of bone remodeling based on damage mechanics].
Zeman ME; García JM; Doblaré M
Acta Cient Venez; 2003; 54(1):36-42. PubMed ID: 14515765
[TBL] [Abstract][Full Text] [Related]
10. Optimizing the management of postmenopausal osteoporosis with bisphosphonates: the emerging role of intermittent therapy.
Miller PD
Clin Ther; 2005 Apr; 27(4):361-76. PubMed ID: 15922811
[TBL] [Abstract][Full Text] [Related]
11. Can the increase of bone mineral density following bisphosphonates treatments be explained by biomechanical considerations?
Pioletti DP; Rakotomanana LR
Clin Biomech (Bristol, Avon); 2004 Feb; 19(2):170-4. PubMed ID: 14967580
[TBL] [Abstract][Full Text] [Related]
12. Alendronate prevents further bone loss in renal transplant recipients.
Giannini S; D'Angelo A; Carraro G; Nobile M; Rigotti P; Bonfante L; Marchini F; Zaninotto M; Dalle Carbonare L; Sartori L; Crepaldi G
J Bone Miner Res; 2001 Nov; 16(11):2111-7. PubMed ID: 11697808
[TBL] [Abstract][Full Text] [Related]
13. Early changes in biochemical markers of bone turnover predict the long-term response to alendronate therapy in representative elderly women: a randomized clinical trial.
Greenspan SL; Parker RA; Ferguson L; Rosen HN; Maitland-Ramsey L; Karpf DB
J Bone Miner Res; 1998 Sep; 13(9):1431-8. PubMed ID: 9738515
[TBL] [Abstract][Full Text] [Related]
14. Clinical evaluation of novel bisphosphonate dosing regimens in osteoporosis: the role of comparative studies and implications for future studies.
Cosman F; Borges JL; Curiel MD
Clin Ther; 2007 Jun; 29(6):1116-27. PubMed ID: 17692726
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and safety of alendronate for the treatment of osteoporosis in diffuse connective tissue diseases in children: a prospective multicenter study.
Bianchi ML; Cimaz R; Bardare M; Zulian F; Lepore L; Boncompagni A; Galbiati E; Corona F; Luisetto G; Giuntini D; Picco P; Brandi ML; Falcini F
Arthritis Rheum; 2000 Sep; 43(9):1960-6. PubMed ID: 11014345
[TBL] [Abstract][Full Text] [Related]
16. Treatment with alendronate plus calcium, alendronate alone, or calcium alone for postmenopausal low bone mineral density.
Bonnick S; Broy S; Kaiser F; Teutsch C; Rosenberg E; DeLucca P; Melton M
Curr Med Res Opin; 2007 Jun; 23(6):1341-9. PubMed ID: 17594775
[TBL] [Abstract][Full Text] [Related]
17. Effects of oral alendronate in elderly patients with osteoporosis and mild primary hyperparathyroidism.
Rossini M; Gatti D; Isaia G; Sartori L; Braga V; Adami S
J Bone Miner Res; 2001 Jan; 16(1):113-9. PubMed ID: 11149474
[TBL] [Abstract][Full Text] [Related]
18. The upper GI safety and tolerability of oral alendronate at a dose of 70 milligrams once weekly: a placebo-controlled endoscopy study.
Lanza F; Sahba B; Schwartz H; Winograd S; Torosis J; Quan H; Reyes R; Musliner T; Daifotis A; Leung A
Am J Gastroenterol; 2002 Jan; 97(1):58-64. PubMed ID: 11808969
[TBL] [Abstract][Full Text] [Related]
19. Randomized trial of effect of alendronate continuation versus discontinuation in women with low BMD: results from the Fracture Intervention Trial long-term extension.
Ensrud KE; Barrett-Connor EL; Schwartz A; Santora AC; Bauer DC; Suryawanshi S; Feldstein A; Haskell WL; Hochberg MC; Torner JC; Lombardi A; Black DM;
J Bone Miner Res; 2004 Aug; 19(8):1259-69. PubMed ID: 15231012
[TBL] [Abstract][Full Text] [Related]
20. Prevention of bone loss in paraplegics over 2 years with alendronate.
Zehnder Y; Risi S; Michel D; Knecht H; Perrelet R; Kraenzlin M; Zäch GA; Lippuner K
J Bone Miner Res; 2004 Jul; 19(7):1067-74. PubMed ID: 15176988
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
